A BIOEQUIVALENCE STUDY OF 2 BRANDS OF DOXYCYCLINE CAPSULES

被引：3

作者：

SAKET, M

QAISI, A

ABDELRAZZAK, M

AMRO, B

TUTUNJI, M

GHARAIBEH, M

ZMEILI, S

MUTI, H

机构：

[1] UNIV JORDAN,FAC MED,AMMAN,JORDAN

[2] UNIV JORDAN,FAC SCI,AMMAN,JORDAN

[3] DAR AL DAWA DEV & INVESTMENT CO,NAUR,JORDAN

来源：

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 1993年 / 54卷 / 01期

关键词：

D O I：

10.1016/S0011-393X(05)80613-7

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Bioequivalence of two preparations of doxycycline (Doxydar(TM) 100-mg capsules and Vibramycin(TM) 100-mg capsules) were compared in a two-way crossover study. Pharmacokinetic parameters were determined for both formulations, including area under the concentration-time curve, mean maximum plasma concentration, time to maximum concentration, half-life, and the terminal rate of elimination. Statistical analysis revealed that differences between the two formulations were not statistically significant. Quality control data, including assay and disintegration, indicated that both products met the in-house specifications. It is concluded that Doxydar 100 mg is bioequivalent to Vibramycin 100 mg.

引用

页码：15 / 22

页数：8

共 11 条

[1]

ENGLISH A R, 1974, Opuscula Medica Supplementum, V33, P11

[2] DISTRIBUTION AND EXCRETION OF DOXYCYCLINE IN MAN [J].